Rescuing compound bioactivity in a secondary cell-based screening by using γ-cyclodextrin as a molecular carrier

References

• IngleseJJohnsonRLSimeonovAHigh-throughput screening assays for the identification of chemical probesNat Chem Biol2007346647917637779
   PubMed Web of Science ®Google Scholar
• BleicherKHBöhmHJMüllerKAlanineAIHit and lead generation: beyond high-throughput screeningNat Rev Drug Discov20032536937812750740
   PubMed Web of Science ®Google Scholar
• Nature Outlook: Hepatitis CNature2011474S1S21
   PubMedGoogle Scholar
• MoradpourDPeninFRiceCMReplication of hepatitis C virusNat Rev Microbiol20075645346317487147
   PubMed Web of Science ®Google Scholar
• LangeCMZeuzemSPerspectives and challenges of interferon-free therapy for chronic hepatitis CJ Hepatol201358358359223104162
   PubMed Web of Science ®Google Scholar
• BaconBRGordonSCLawitzEBoceprevir for previously treated chronic HCV genotype 1 infectionN Engl J Med2011364131207121721449784
   PubMed Web of Science ®Google Scholar
• JacobsonIMMcHutchisonJGDusheikoGTelaprevir for previously untreated chronic hepatitis C virus infectionN Engl J Med2011364252405241621696307
   PubMed Web of Science ®Google Scholar
• PoordadFMcConeJJrBaconBRBoceprevir for untreated chronic HCV genotype 1 infectionN Engl J Med2011364131195120621449783
   PubMed Web of Science ®Google Scholar
• ZeuzemSAndreonePPolSTelaprevir for retreatment of HCV infectionN Engl J Med2011364252417242821696308
   PubMed Web of Science ®Google Scholar
• GaneEJStedmanCAHylandRHEfficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infectionGastroenterology2014146373674324262278
   PubMed Web of Science ®Google Scholar
• RosenquistÅSamuelssonBJohanssonPODiscovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitorJ Med Chem20145751673169324446688
   PubMed Web of Science ®Google Scholar
• SarkarSLimJKAdvances in interferon-free hepatitis C therapy: 2014 and beyondHepatology20145941641164424590916
   PubMed Web of Science ®Google Scholar
• AbianONeiraJLVelazquez-CampoyAThermodynamics of zinc binding to hepatitis C virus NS3 protease: A folding by binding eventProteins200977362463619536779
   PubMed Web of Science ®Google Scholar
• AbianOVegaSNeiraJLVelazquez-CampoyAConformational stability of hepatitis C virus NS3 proteaseBiophys J201099113811382021112306
   PubMed Web of Science ®Google Scholar
• AbianOVegaSSanchoJVelazquez-CampoyAAllosteric Inhibitors of the NS3 Protease From the Hepatitis C VirusPLoS One201387e6977323936097
   PubMed Web of Science ®Google Scholar
• LiSPurdyWCCyclodextrins and their applications in analytical chemistryChem Rev199292614571470
   Web of Science ®Google Scholar
• VilliersASur la fermentation de la fecule par l’action du ferment butyrique [The fermentation of starch by the action of butyric]C R Acad Sci1981112536538 French
   Google Scholar
• SaengerWCyclodextrin inclusion compounds in research and industryAngew Chem Int Ed Engl1980195344362
   Web of Science ®Google Scholar
• UekamaKHirayamaFIrieTCyclodextrin drug carrier systemsChem Rev19989852045207611848959
   PubMed Web of Science ®Google Scholar
• SinghMSharmaRBanerjeeUCBiotechnological applications of cyclodextrinsBiotechnol Adv2002205–634135914550020
   PubMed Web of Science ®Google Scholar
• VillalongaRCaoRFragosoASupramolecular chemistry of cyclodextrins in enzyme technologyChem Rev200710773088311617590054
   PubMed Web of Science ®Google Scholar
• RekharskyMVInoueYComplexation thermodynamics of cyclodextrinsChem Rev19989858751917
   Web of Science ®Google Scholar
• FuchsRHabermannNKlufersPMultinuclear sandwich-type complexes of deprotonated β-cyclodextrin and copper(II) ionsAngew Chem Int Ed Eng1993326852854
   Web of Science ®Google Scholar
• IrieTUekamaKCyclodextrins in peptide and protein deliveryAdv Drug Deliv Rev199936110112310837711
   PubMed Web of Science ®Google Scholar
• LysikMAWu-PongSInnovations in oligonucleotide drug deliveryJ Pharm Sci20039281559157312884243
   PubMed Web of Science ®Google Scholar
• IrieTUekamaKPharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluationJ Pharm Sci19978621471629040088
   PubMed Web of Science ®Google Scholar
• BrewsterMELoftssonTCyclodextrins as pharmaceutical solubilizersAdv Drug Deliv Rev200759764566617601630
   PubMed Web of Science ®Google Scholar
• CarrierRLMillerLAAhmedIThe utility of cyclodextrins for enhancing oral bioavailabilityJ Control Release20071232789917888540
   PubMed Web of Science ®Google Scholar
• HirayamaFUekamaKCyclodextrin-based controlled drug release systemAdv Drug Deliv Rev199936112514110837712
   PubMed Web of Science ®Google Scholar
• DavisMEBrewsterMECyclodextrin-based pharmaceutics: past, present, and futureNat Rev Drug Discov20043121023103515573101
   PubMed Web of Science ®Google Scholar
• LoftssonTBrewsterMEPharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranesJ Pharm Pharmacol20116391119113521827484
   PubMed Web of Science ®Google Scholar
• MatsudaHArimaHCyclodextrins in transdermal and rectal deliveryAdv Drug Deliv Rev19993618099
   Web of Science ®Google Scholar
• LoftssonTJarvinenTCyclodextrins in ophthalmic drug deliveryAdv Drug Deliv Rev1999361597910837709
   PubMed Web of Science ®Google Scholar
• MerkusFWVerhoefJCMarttinECyclodextrins in nasal drug deliveryAdv Drug Deliv Rev1999361415710837708
   PubMed Web of Science ®Google Scholar
• SzenteLSzejtliJHighly soluble cyclodextrin derivatives: chemistry, properties, and trends in developmentAdv Drug Deliv Rev1999361172810837706
   PubMed Web of Science ®Google Scholar
• DucheneDPonchelGWouessidjeweDCyclodextrins in targeting application to nanoparticlesAdv Drug Deliv Rev1999361294010837707
   PubMed Web of Science ®Google Scholar
• SinhaVRNandaAKumriaRCyclodextrins as sustained-release carriersPharmaceutical Technology2002443644
   Google Scholar
• LoftssonTDucheneDCyclodextrins and their pharmaceutical applicationsInt J Pharm20073291–211117137734
   PubMed Web of Science ®Google Scholar
• FiniPCastagnoloMCatucciLCosmaPAgostianoAInclusion complexes of Rose Bengal and cyclodextrinsThermochim Acta20044183338
   Web of Science ®Google Scholar
• SunDZQiuXMLiLWeiXLYinBLA study of a-cyclodextrin with a group of cationic Gemini surfactants utilizing isothermal titration calorimetry and NMRJ Chem Thermodyn2006386773777
   Web of Science ®Google Scholar
• LiuYCaoRChenYHeJYEffect of b-cyclodextrin charge type on the molecular recognition thermodynamics of reactions with (ferrocenylmethyl)dimethylaminium derivativesJ Phys Chem B200811251445145018193857
   PubMed Web of Science ®Google Scholar
• DenadaiAMTeixeiraKISantoroMMPimentaAMCortesMESinisterraRDSupramolecular self-assembly of b-cyclodextrin: an effective carrier of the antimicrobial agent chlorhexidineCarbohydr Res2007342152286229617618611
   PubMed Web of Science ®Google Scholar
• HeYKingMSKempfDJRelative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon systemAntimicrob Agents Chemother20085231101111018086851
   PubMed Web of Science ®Google Scholar
• CremadesNVelazquez-CampoyAMartinez-JulvezMDiscovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infectionACS Chem Biol200941192893819725577
   PubMed Web of Science ®Google Scholar
• PeyALYingMCremadesNIdentification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuriaJ Clin Invest200811882858286718596920
   PubMed Web of Science ®Google Scholar
• TalianiMBianchiENarjesFA continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substratesAnal Biochem1996240160678811880
   PubMed Web of Science ®Google Scholar
• MorrisGMGoodsellDSHallidayRSAutomated docking using a Lamarckian genetic algorithm and an empirical binding free energy functionJ Comput Chem19981916391662
   Web of Science ®Google Scholar
• SolisFJWetsRJMinimization by Random Search TechniquesMathematics of Operations Research198161930
   Web of Science ®Google Scholar
• CourcambeckJBouzidiMPerbostRResistance of hepatitis C virus to NS3-4A protease inhibitors: Mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutationsAntivir Ther200411784785517302247
   PubMed Web of Science ®Google Scholar
• SusserSVermehrenJForestierNAnalysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevirJ Clin Virol201152432132721924672
   PubMed Web of Science ®Google Scholar
• BlightKJMcKeatingJARiceCMHighly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replicationJ Virol20027624130011301412438626
   PubMed Web of Science ®Google Scholar
• LohmannVKornerFKochJHerianUTheilmannLBartenschlagerRReplication of subgenomic hepatitis C virus RNAs in a hepatoma cell lineScience1999285542411011310390360
   PubMed Web of Science ®Google Scholar
• UrbaniABazzoRNardiMCThe metal binding site of the hepatitis C virus NS3 protease. A spectroscopic investigationJ Biol Chem19982733018760187699668049
   PubMed Web of Science ®Google Scholar
• VegaSNeiraJLMarcuelloCNS3 protease from hepatitis C virus: Biophysical studies on an intrinsically disordered protein domainInt J Mol Sci2013147132821330623803659
   PubMed Web of Science ®Google Scholar